Mobilising Meaningful Pharma-Patient Collaboration┃Bronwyn Lewis

20/05/2024 1h 1min Episodio 3
Mobilising Meaningful Pharma-Patient Collaboration┃Bronwyn Lewis

Listen "Mobilising Meaningful Pharma-Patient Collaboration┃Bronwyn Lewis"

Episode Synopsis

On this episode, we speak with Bronwyn Lewis, Global Head of Patient Engagement at Boehringer Ingelheim. Drawing on her 20+ years of experience across diverse roles in the pharmaceutical industry, Bronwyn offers deep insights into how the industry is perceiving and  responding to the call for deeper patient engagement, the challenges and opportunities for better multi-stakeholder collaboration, and her vision for the future.Note: In the episode, Bronwyn mentions  Boehringer Ingelheim’s Research & Development (R&D) investment data for the year 2022. In 2023, Boehringer Ingelheim’s R&D investments increased by 14.2% to EUR 5.8 billion. R&D investments were substantial, at 22.5% of net sales (source: Boehringer Ingelheim strong growth pipeline acceleration 2023 | Boehringer Ingelheim (boehringer-ingelheim.com)).Chapters00:00 - Introductions01:03 - Defining patient engagement from the industry perspective04:06 - Bronwyn's journey into patient engagement06:51 - The Patient Engagement function at Boehringer Ingelheim10:39 - Composition of Patient Engagement teams in pharma    13:22 - Aligning the motivations of pharma and patient groups16:42 - Barriers to pharma–patient collaboration20:23 - Justifying return on investment (ROI) 26:17 - Patient engagement touchpoints and activities29:16 - Matching best-fit patients to targeted activities 32:21 - Systemic integration of patient insights into all pharma operations 36:25 - Examples of patient insights influencing decisions38:28 - Boehringer Ingelheim's Global Patient Partnership Summit44:26 - Collaboration among industry stakeholders47:56 - Visualizing the future56:14 - Advice for patients and industry stakeholders 58:13 - Reflections with Caitlin and ClarindaResources and abbreviations mentionedBoehringer IngelheimCanadian Pulmonary Fibrosis FoundationIPF - Idiopathic pulmonary fibrosisPFMD - Patient-Focused Medicines DevelopmentEUPATI Connect ROI - Return on investmentHTA - Health Technology Assessment FDA - U.S. Food and Drug Administration EMA - European Medicines AgencyPFMD - Pharmaceuticals and Medical Devices AgencyGPPS - Global Patient Partnership SummitPatient Information ForumThe PIF TICKAtomic Habits by James ClearEUPATI Fundamentals trainingHave feedback or suggestions for us? We'd love to hear from you!Website: notjustpatients.comLinkedIn: Not Just PatientsEmail: [email protected]

More episodes of the podcast Not Just Patients